The UK's National Institute for Health and Care Excellence has approved Pfizer's Vizimpro, or dacomitinib, as a first-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer with epidermal growth factor receptor mutation. NICE issued a guidance recommending the therapy for National Health Service use.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.